Simvastatin-induced rhabdomyolysis and acute renal injury
Abstract
Simvastatin is one of the most commonly prescribed CoA reductase inhibitors. The safety profile of this drug has been widely discussed in the medical and consumer advocacy communities. Like other statins, simvastatin can cause a serious and potentially life-threatening complication: rhabdomyolysis. We describe a case of simvastatin-induced rhabdomyolysis complicated by acute renal failure requiring urgent hemodialysis. The relative safety of simvastatin compared to other HMG-CoA reductase inhibitors and the conditions that can potentiate its toxicity are discussed. The clinical features of rhabdomyolysis, and subsequent acute renal failure, and their treatment modalities are presented.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Allopathic hypolipidemic drugs are available but have adverse effects and contraindications.
“Allopathic hypolipidemic drugs are available at large in the market, but with their own adverse effects and contraindications [3].”
From Regulatory Efficacy of the Polyunsaturated Fatty Acids from Microalgae Spirulina platensis on Lipid Metabolism and Gut Microbiota in High-Fat Diet Rats (2018) · cites this paper as [3]
Cites
Incidence of hospitalized rhabdomyolysis in patients treated with lipid-lowering drugs
Graham, D. J. (2004) · JAMA · doi:10.1001/jama.292.21.2585 · Cited by 875 · see citing works
Statin Safety: A Systematic Review
Law, M., & Rudnicka, A. R. (2006) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2005.12.010 · Cited by 808 · see citing works
benefit-risk assessment of Rosuvastatin 10 to 40 milligrams
Brewer, H. B. (2003) · The American Journal of Cardiology · doi:10.1016/s0002-9149(03)00779-3 · Cited by 198 · see citing works
Pedersen, T. R., & Tobert, J. A. (2004) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.5.12.2583 · Cited by 145 · see citing works
Shepherd, J., Hunninghake, D. B., Stein, E. A., Kastelein, J. J. P., Harris, S., Pears, J. S., & Hutchinson, H. G. (2004) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2004.06.049 · Cited by 137 · see citing works
Concomitant use of cytochrome P450 3A4 inhibitors and simvastatin
Gruer, P. J. K., Vega, J. M., Mercuri, M. F., Dobrinska, M. R., & Tobert, J. A. (1999) · The American Journal of Cardiology · doi:10.1016/s0002-9149(99)00442-7 · Cited by 130 · see citing works
Efficacy and safety of rosuvastatin in treatment of dyslipidemia
McKenney, J. M. (2005) · American Journal of Health-System Pharmacy · doi:10.1093/ajhp/62.10.1033 · Cited by 83 · see citing works
Rosuvastatin safety: lessons from the FDA review and post-approval surveillance
Davidson, M. H. (2004) · Expert Opinion on Drug Safety · doi:10.1517/14740338.3.6.547 · Cited by 80 · see citing works
Rhabdomyolysis in Association with Simvastatin and Amiodarone
Roten, L., Schoenenberger, R. A., Krähenbühl, S., & Schlienger, R. G. (2004) · Annals of Pharmacotherapy · doi:10.1345/aph.1d498 · Cited by 76 · see citing works
Scott, L. J., Curran, M. P., & Figgitt, D. P. (2004) · American Journal of Cardiovascular Drugs · doi:10.2165/00129784-200404020-00005 · Cited by 74 · see citing works
Potential Adverse Effects of Statins on Muscle
Tomlinson, S. S., & Mangione, K. K. (2005) · Physical Therapy · doi:10.1093/ptj/85.5.459 · Cited by 68 · see citing works
Simvastatin–Fluconazole Causing Rhabdomyolysis
Shaukat, A., Beneklı, M., Vladutiu, G. D., Slack, J. L., Wetzler, M., & Baer, M. R. (2003) · Annals of Pharmacotherapy · doi:10.1345/aph.1c467 · Cited by 56 · see citing works
Rhabdomyolysis Associated With Pomegranate Juice Consumption
Sorokin, A. V., Duncan, B. H., Panetta, R., & Thompson, P. D. (2006) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2006.03.057 · Cited by 49 · see citing works
Risk Factors for Rhabdomyolysis with Simvastatin and Atorvastatin
Ronaldson, K. J., Shea, J. M. O., & Boyd, I. W. (2006) · Drug Safety · doi:10.2165/00002018-200629110-00005 · Cited by 47 · see citing works
Safety Profile of Rosuvastatin
Kasliwal, R., Wilton, L., Cornelius, V. R., Aurich‐Barrera, B., & Shakir, S. (2007) · Drug Safety · doi:10.2165/00002018-200730020-00005 · Cited by 45 · see citing works
Rhabdomyolysis and Acute Renal Failure After Fire Ant Bites
Koya, S., Crenshaw, D., & Agarwal, A. (2007) · Journal of General Internal Medicine · doi:10.1007/s11606-006-0025-z · Cited by 43 · see citing works
Csako, G., McGriff, N. J., Rotman-Pikielny, P., Sarlis, N. J., & Pucino, F. (2001) · Annals of Pharmacotherapy · doi:10.1345/aph.1a031 · Cited by 40 · see citing works
Fatal Rhabdomyolysis Caused by Lipid-Lowering Therapy
Federman, D. G., HUSSAIN, F., & WALTERS, J. B. (2001) · Southern Medical Journal · doi:10.1097/00007611-200194100-00017 · Cited by 31 · see citing works
Simvastatin-Induced Rhabdomyolysis in a Patient with Chronic Renal Failure
Shohaib, S. A. (2000) · American Journal of Nephrology · doi:10.1159/000013589 · Cited by 28 · see citing works
Rosuvastatin for the Treatment of Hypercholesterolemia
Culhane, N. S., Lettieri, S. L., & Skae, J. R. (2005) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.2005.25.7.990 · Cited by 25 · see citing works
Rosuvastatin (Crestor) and rhabdomyolysis
Wooltorton, E. (2004) · Canadian Medical Association Journal · doi:10.1503/cmaj.1041051 · Cited by 21 · see citing works
Rosuvastatin: an independent analysis of risks and benefits.
Zipes, D. P., Zvaifler, N. J., Glassock, R. J., Gilman, S., Muñoz, Á., Gogolak, V., Gordis, L., Dedon, P. C., Guengerich, F. P., Wasserman, S. I., et al. (2006) · PubMed Central · Cited by 19 · see citing works
Rosuvastatin: A High-Potency HMG-CoA Reductase Inhibitor
Lopez, L. M. (2005) · Journal of the American Pharmacists Association · doi:10.1331/1544345054475522 · Cited by 14 · see citing works
Middleton, A., Binbrek, A. S., Fonseca, F. A. H., Wilpshaar, W., Watkins, C. L., & Strandberg, T. E. (2006) · Current Medical Research and Opinion · doi:10.1185/030079906x100177 · Cited by 14 · see citing works
Simvastatin-induced rhabdomyolysis
Ho, M. R., Baker, J. E., & Miller, A. L. (2004) · The American Journal of Emergency Medicine · doi:10.1016/j.ajem.2004.02.023 · Cited by 2 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Li, L., Guo, W., Zhang, W., Xu, J., Qian, M., Bai, W., Zhang, Y., Rao, P., Ni, L., & Lv, X. (2019) · Food & Function · doi:10.1039/c9fo00075e · Cited by 184 · see citing works
Li, T., Huang, Z., Jia, R., Lv, X., Zhao, C., & Liu, B. (2021) · Food Research International · doi:10.1016/j.foodres.2021.110530 · Cited by 122 · see citing works
Li, T.-T., Liu, Y.-Y., Wan, X.-Z., Huang, Z.-R., Liu, B., & Zhao, C. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19103075 · Cited by 103 · see citing works
Li, T., Tong, A.-J., Liu, Y.-Y., Huang, Z., Wan, X., Pan, Y., Jia, R., Liu, B., Chen, X., & Zhao, C. (2019) · Food and Chemical Toxicology · doi:10.1016/j.fct.2019.06.005 · Cited by 96 · see citing works
Lipid lowering agents of natural origin: An account of some promising chemotypes
Singh, S. P., & Sashidhara, K. V. (2017) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2017.09.020 · Cited by 66 · see citing works
Hu, R., Guo, W., Huang, Z., Li, L., Liu, B., & Lv, X. (2018) · Journal of Functional Foods · doi:10.1016/j.jff.2018.05.020 · Cited by 62 · see citing works
The Role of Endothelial Progenitor Cells in Acute Kidney Injury
Becherucci, F., Mazzinghi, B., Ronconi, E., Peired, A. J., Lazzeri, E., Sagrinati, C., Romagnani, P., & Lasagni, L. (2009) · Blood Purification · doi:10.1159/000202005 · Cited by 38 · see citing works
The function and application of edible fungal polysaccharides
Zhang, Q., Xu, Y., Xie, L., Shu, X., Zhang, S., Wang, Y., Wang, H., Dong, Q., & Peng, W. (2024) · Advances in applied microbiology · doi:10.1016/bs.aambs.2024.02.005 · Cited by 24 · see citing works
Zhao, L., Wu, Y., & Yu, B. (2020) · Brazilian Journal of Medical and Biological Research · doi:10.1590/1414-431x20199201 · Cited by 20 · see citing works
Molecular mechanisms of toxicity of simvastatin, widely used cholesterol-lowering drug. A review
Kaminsky, Y. G., & Kosenko, E. A. (2009) · Open Medicine · doi:10.2478/s11536-009-0123-5 · Cited by 12 · see citing works
Néphrotoxicité des médicaments
Zimner‐Rapuch, S., Amet, S., Janus, N., Deray, G., & Launay‐Vacher, V. (2013) · Revue Francophone des Laboratoires · doi:10.1016/s1773-035x(13)72182-8 · Cited by 4 · see citing works
Blood cholesterol and mitochondrial toxicity of simvastatin
Kaminsky, Y. G., & Kosenko, E. A. (2011) · Biology Bulletin Reviews · doi:10.1134/s2079086411040013 · Cited by 2 · see citing works
HMG coenzyme-A reductase inhibitors
(2015) · Elsevier eBooks · doi:10.1016/b978-0-444-53717-1.00850-7 · Cited by 2 · see citing works
Bullé, D. J., Vitalis, R., Paza, L., da Silva, R., dos Santos, C. E., & Renner, J. D. P. (2015) · Cinergis · doi:10.17058/cinergis.v16i2.6104 · Cited by 1 · see citing works
Drugs that affect lipid metabolism
Aronson, J. K. (2010) · Side effects of drugs annual · doi:10.1016/s0378-6080(10)32044-7 · Cited by 1 · see citing works
Current awareness: Pharmacoepidemiology and drug safety
(2008) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.1493
- Authors
- Waness, A., Bahlas, S., & Al Shohaib, S.
- Affiliations
- King Abdulaziz Medical City (SA)
- ORCID
- Bahlas, Sami
- Venue
- Blood Purification
- Publisher
- S. Karger AG
- Published
- 2008
- Volume
- 26
- Issue
- 4
- Pages
- 394-398
- ISSN
- 0253-5068 (ISSN-L)
- 1421-9735
- OpenAlex
- W2093727198
- Cited by
- 16
- References
- 25
- Citations by year
- 2024: 1 · 2021: 1 · 2020: 1 · 2019: 2 · 2018: 2 · 2017: 1 · 2015: 2 · 2013: 1
- FWCI
- 1.76
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Blood Purification (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Surgery › Muscle and Compartmental Disorders
- Health Sciences › Medicine › Nephrology › Acute Kidney Injury Research
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Methemoglobinemia and Tumor Lysis Syndrome
- Keywords
- simvastatin, rhabdomyolysis, acute kidney injury, statin toxicity, statins, adverse drug reactions, hemodialysis, drug safety
- MeSH terms
- Acute Disease, Female, Renal Dialysis, Humans, Kidney Diseases, Middle Aged, Rhabdomyolysis, Treatment Outcome, Simvastatin
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
